Rheumatoid arthritis

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

Rene Westhovens, Manuel Robles, Antonio Carlos Ximenes, Jurgen Wollenhaupt, Patrick Durez, Juan Gomez-Reino, Walter Grassi, Boulos Haraoui, William Shergy, Sung-Hwan Park, Harry Genant, Charles Peterfy, Jean-Claude Becker, Bindu Murthy

10.1136/annrheumdis-2014-206149

December 30, 2014

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

M Østergaard, L T H Jacobsson, C Schaufelberger, M Sejer Hansen, J W J Bijlsma, A Dudek, M Rell-Bakalarska, F Staelens, R Haake, B Sundman-Engberg, H Bliddal

10.1136/annrheumdis-2014-206359

December 15, 2014

A circulating reservoir of pathogenic-like CD4 T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment

Roberto Spreafico, Maura Rossetti, Jorg van Loosdregt, Carol A Wallace, Margherita Massa, Silvia Magni-Manzoni, Marco Gattorno, Alberto Martini, Daniel J Lovell, Salvatore Albani

10.1136/annrheumdis-2014-206226

December 12, 2014

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Edward C Keystone, Peter C Taylor, Edit Drescher, Douglas E Schlichting, Scott D Beattie, Pierre-Yves Berclaz, Chin H Lee, Rosanne K Fidelus-Gort, Monica E Luchi, Terence P Rooney, William L Macias, Mark C Genovese

10.1136/annrheumdis-2014-206478

November 27, 2014

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

D L Boyle, K Soma, J Hodge, A Kavanaugh, D Mandel, P Mease, R Shurmur, A K Singhal, N Wei, S Rosengren, I Kaplan, S Krishnaswami, Z Luo, J Bradley, G S Firestein

10.1136/annrheumdis-2014-206028

November 14, 2014

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study

Atul Deodhar, Jürgen Braun, Robert D Inman, Désirée van der Heijde, Yiying Zhou, Stephen Xu, Chenglong Han, Benjamin Hsu

10.1136/annrheumdis-2014-205862

November 11, 2014

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

Paul Emery, Gerd R Burmester, Vivian P Bykerk, Bernard G Combe, Daniel E Furst, Emilie Barré, Chetan S Karyekar, Dennis A Wong, Tom W J Huizinga

10.1136/annrheumdis-2014-206106

November 3, 2014

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

Charles Peterfy, Paul Emery, Paul P Tak, Mikkel Østergaard, Julie DiCarlo, Kati Otsa, Federico Navarro Sarabia, Karel Pavelka, Marie-Agnes Bagnard, Lykke Hinsch Gylvin, Corrado Bernasconi, Annarita Gabriele

10.1136/annrheumdis-2014-206015

October 29, 2014

Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study

Alexis Ogdie, YiDing Yu, Kevin Haynes, Thorvardur Jon Love, Samantha Maliha, Yihui Jiang, Andrea B Troxel, Sean Hennessy, Steven E Kimmel, David J Margolis, Hyon Choi, Nehal N Mehta, Joel M Gelfand

10.1136/annrheumdis-2014-205675

October 28, 2014

Choline kinase inhibition in rheumatoid arthritis

M Guma, E Sanchez-Lopez, A Lodi, R Garcia-Carbonell, S Tiziani, M Karin, J C Lacal, G S Firestein

10.1136/annrheumdis-2014-205696

October 1, 2014